Commonly, Ki67 has been proposed as a useful clinical marker for BC subtype classification, prognosis, and prediction of therapeutic response.41 A recent review study conducted by Zhang et al assessed the role of Ki67 in NCT therapy for BC.41 They concluded that NCT is the first choice for TNBC and HER2-positive BC. The gene discussed is ERBB2; the disease is breast cancer.